Please login to the form below

VPAS

This page shows the latest VPAS news and features for those working in and with pharma, biotech and healthcare.

and VPAS in the UK, look minor.

AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement

AbbVie and Eli Lilly have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), according to an update by the Association of the British Pharmaceutical Industry (ABPI). ... Introduced in 2019, the VPAS deal is a long-standing
Europe responding to gene therapy challenge, but picture remains fragmented

The new framework will build on the new UK-wide pricing agreement, the Voluntary Scheme for Branded Medicines Pricing and Access ( VPAS), and is expected to go out to industry for
NHS England’s medicines chief: stop ‘salami slicing’ and get faster market access

Dark's arrival coincided with the signing of a new five-year Voluntary Price and Access Scheme (VPAS), which caps NHS expenditure on medicines, but also allows NHS England to agree ... mindful of that, maintaining a tough bargaining position, even though
NHS Long-term Plan welcomed – but warnings on staff and overpromising

UK pharma industry response. The new Long-term Plan coincides with the launch of a new five year Voluntary Pricing and Access Scheme (VPAS) covering branded medicines in the UK. ... He also hailed the introduction of the VPAS, saying it “should see the

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Evolution or revolution: the latest review of NICE methods

What is not part of the review – because it’s a done deal as part of VPAS – is the basic cost- effectiveness threshold. ... Leela worked as an advisor to the Department of Health and Social Care on the 2019 Voluntary Scheme for Branded Medicines
The UK’s new medicines pricing deal – opportunities and risks for pharma

So what are the big differences between the 2014 PPRS and the 2019 VPAS? ... Overall VPAS covers more than 85% of all NHS spend on branded drugs.
The UK’s new five-year pricing agreement

The UK has a new five-year Voluntary Pricing and Access Scheme (VPAS) for branded medicines, which came into force on 1 January 2019.
Comment: the new UK pricing deal – welcome news, but lessons to be learned

Leslie Galloway, chairman of EMIG reflects on the new UK government-pharma industry pricing agreement

More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.

VPAS: The importance of making the right arguments, even in challenging times

The environment to argue for a more generous settlement for industry, through the controversial voluntary scheme for branded medicines pricing and access ( VPAS), could not be tougher. ... Taking a closer look at all the commentary since The Telegraph
Let's be ambitious for patients and life sciences investment in Global Britain

Industry argues that the remarkable VPAS deal which caps NHS spending on medicines would cover any costs. ... A new 10-year VPAS with more substantial and defined NICE reform locked in?
Hanover Communications

VPAS: The importance of making the right arguments, even in challenging times. ... Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals.
Volt Pharma Associates

VPA supports life sciences companies, investors and academic institutes in developing new products, technologies and innovative approaches. ... VPA’s aim is to solve our clients’ product research, development and commercialisation challenges so they

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

No results were found

Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

The importance of accelerating clinical trial diversity: Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications: There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day: At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....

Email:
Password: